United Therapeutics(UTHR)
$595.66+7.05 (+1.20%)
UTHR
United Therapeutics stock forecast
$595.66
At close:+7.05 (+1.20%)
Want to see UTHR full AI Analyst Report?
United Therapeutics (UTHR) Stock Forecast & Price Target
789 Followers
UTHR Analyst Ratings
Moderate Buy
11Buy2Hold1Sell
Based on 14 analysts giving stock ratings to United Therapeutics in the past 3 months
UTHR Stock 12 Month Forecast
Average Price Target
$682.71▲(14.61% Upside)Based on 14 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $682.71 with a high forecast of $850.00 and a low forecast of $368.00. The average price target represents a 14.61% change from the last price of $595.66.
Past 12 Months12 Month ForecastJan2026Oct2026
High$850.00
Average$682.71
Low$368.00
Highest Price TargetHighest$850.00Average Price Target$682.71Lowest Price TargetLowest$368.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Matthew Caufield | H.C. Wainwright | $660 | buy | 10.80%Upside | Initiated | 11/09/26 | ||
| Benjamin Burnett | Wells Fargo | $700→$703 | buy | 18.02%Upside | Assigned | 11/05/26 | ||
| Terence Flynn | Morgan Stanley | $566→$568 | hold | -4.64%Downside | Assigned | 11/05/26 | ||
| Joseph Thome | TD Cowen | $675→$700 | buy | 17.52%Upside | Assigned | 11/05/26 | ||
| Roanna Ruiz | Leerink Partners | $725 | buy | 21.71%Upside | Reiterated | 11/05/26 | ||
| Jason Gerberry | Bank of America Securities | $559→$650 | hold | 9.12%Upside | Reiterated | 11/04/26 | ||
| Julian Harrison | BTIG | $728→$768 | buy | 28.93%Upside | Reiterated | 11/04/26 | ||
| Lisa Walter | RBC Capital | $697→$725 | buy | 21.71%Upside | Reiterated | 11/04/26 | ||
| Jessica Fye | J.P. Morgan | $710→$695 | buy | 16.68%Upside | Assigned | 10/28/26 | ||
| Olivia Brayer | Cantor Fitzgerald | $700→$850 | buy | 42.70%Upside | Reiterated | 10/26/26 | ||
| Tiago Fauth | Raymond James | $685→$717 | buy | 20.37%Upside | Reiterated | 10/20/26 | ||
| Andrea Newkirk | Goldman Sachs | $321→$368 | sell | -38.22%Downside | Reiterated | 10/15/26 | ||
| Ashwani Verma | UBS | $725 | buy | 21.71%Upside | Reiterated | 10/13/26 | ||
| Roger Song | Jefferies | $704 | buy | 18.19%Upside | Reiterated | 10/01/26 | ||
| Jasper Hellweg | Argus Research | $560 | buy | -5.99%Downside | Assigned | 03/03/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Matthew CaufieldH.C. Wainwright | BuyInitiated$660 | 11/09/26 | 10.80%Upside | ||
| Benjamin BurnettWells Fargo | BuyAssigned$700→$703 | 11/05/26 | 18.02%Upside | ||
| Terence FlynnMorgan Stanley | HoldAssigned$566→$568 | 11/05/26 | -4.64%Downside | ||
| Joseph ThomeTD Cowen | BuyAssigned$675→$700 | 11/05/26 | 17.52%Upside | ||
| Roanna RuizLeerink Partners | BuyReiterated$725 | 11/05/26 | 21.71%Upside | ||
| Jason GerberryBank of America Securities | HoldReiterated$559→$650 | 11/04/26 | 9.12%Upside | ||
| Julian HarrisonBTIG | BuyReiterated$728→$768 | 11/04/26 | 28.93%Upside | ||
| Lisa WalterRBC Capital | BuyReiterated$697→$725 | 11/04/26 | 21.71%Upside | ||
| Jessica FyeJ.P. Morgan | BuyAssigned$710→$695 | 10/28/26 | 16.68%Upside | ||
| Olivia BrayerCantor Fitzgerald | BuyReiterated$700→$850 | 10/26/26 | 42.70%Upside | ||
| Tiago FauthRaymond James | BuyReiterated$685→$717 | 10/20/26 | 20.37%Upside | ||
| Andrea NewkirkGoldman Sachs | SellReiterated$321→$368 | 10/15/26 | -38.22%Downside | ||
| Ashwani VermaUBS | BuyReiterated$725 | 10/13/26 | 21.71%Upside | ||
| Roger SongJefferies | BuyReiterated$704 | 10/01/26 | 18.19%Upside | ||
| Jasper HellwegArgus Research | BuyAssigned$560 | 03/03/26 | -5.99%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering United Therapeutics
3 Months
Success Rate15/20 ratings generated profit
75%
Average Return
+13.48%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +13.48% per trade.
1 Year
Success Rate14/16 ratings generated profit
88%
Average Return
+27.84%
Copying Roger Song's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +27.84% per trade.
2 Years
Success Rate16/16 ratings generated profit
100%
Average Return
+41.28%
Copying Ashwani Verma's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.28% per trade.
UTHR Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 16 | 14 | 16 | 25 | 24 |
| Hold | 4 | 3 | 2 | 3 | 4 |
| Sell | 0 | 0 | 1 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 20 | 17 | 19 | 30 | 30 |
In the current month, UTHR has received 24 Buy Ratings, 4 Hold Ratings, and 2 Sell Ratings. UTHR average Analyst price target in the past 3 months is 682.71.
UTHR Financial Forecast
High$9.28
Consensus$4.95
Low$2.53
UTHR Earnings Forecast
Next quarter’s earnings estimate for UTHR is $4.95 with a range of $2.53 to $9.28. The previous quarter’s EPS was $5.71. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$1.16B
Consensus$862M
Low$693M
UTHR Sales Forecast
Next quarter’s sales forecast for UTHR is $861.62M with a range of $693.18M to $1.16B. The previous quarter’s sales results were $832.50M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
UTHR Stock Forecast FAQ
What is UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is $682.71.
What is UTHR’s upside potential, based on the analysts’ average price target?
United Therapeutics has 14.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is UTHR a Buy, Sell or Hold?
United Therapeutics has a consensus rating of Moderate Buy which is based on 11 buy ratings, 2 hold ratings and 1 sell ratings.
What is United Therapeutics’s price target?
The average price target for United Therapeutics is $682.71. This is based on 14 12-month price targets, issued in the past 3 months. The highest analyst price target is $850.00, the lowest forecast is $368.00. The average price target represents a 14.61% increase from the current price of $595.66.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of UTHR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
